Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised

Janssen, HLA; van Zonneveld, M; Senturk, H; Zeuzem, S; Akarca, US; Cakaloglu, Y; Simon, C; So, TMJ; Gerken, G; de Man, RA; Niesters, HGM; Zondervan, P; Hansen, B; Schalm, SW

doi:10.1016/s0140-6736(05)17701-0

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised

Atıf İçin Kopyala

Janssen H., van Zonneveld M., Senturk H., Zeuzem S., Akarca U., Cakaloglu Y., ...Daha Fazla

LANCET, cilt.365, sa.9454, ss.123-129, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 365 Sayı: 9454
Basım Tarihi: 2005
Doi Numarası: 10.1016/s0140-6736(05)17701-0
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.123-129
İstanbul Üniversitesi Adresli: Hayır

Özet

Background Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response.